These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 1301586

  • 1. BCG versus cytotoxic chemotherapy in the treatment of superficial bladder tumors.
    Boccon-Gibod L.
    Prog Clin Biol Res; 1992; 378():55-7. PubMed ID: 1301586
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [A comparative clinical trial of UFT medication and intravesical BCG in the recurrence of superficial bladder cancer. Study Group of UFT and BCG adjuvant therapy for bladder cancer].
    Oda H, Seki N, Nabeshima S, Oda T, Nishio S, Yokoyama M, Iwata H, Takeuchi M, Matsumoto A, Terado T.
    Gan To Kagaku Ryoho; 1990 Oct; 17(10):2051-5. PubMed ID: 2221929
    [Abstract] [Full Text] [Related]

  • 7. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale, design, and interim analysis of the trial of the South-East Cooperative Urological Group, The Netherlands.
    Witjes WP, van der Meijden PM, Roos EP, Witjes JA, Steerenberg PA, Doesburg W, Debruyne FM.
    Prog Clin Biol Res; 1992 Oct; 378():59-67. PubMed ID: 1301587
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Intravesical chemotherapy in non-muscle-invasive bladder cancer: what schedule and duration of treatment?
    Sylvester RJ.
    Eur Urol; 2007 Oct; 52(4):951-3; discussion 953-4. PubMed ID: 17374437
    [No Abstract] [Full Text] [Related]

  • 10. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation.
    Huncharek M, Kupelnick B.
    Am J Clin Oncol; 2003 Aug; 26(4):402-7. PubMed ID: 12902895
    [Abstract] [Full Text] [Related]

  • 11. Risk-adapted use of intravesical chemotherapy.
    Lerner SP, Au JL.
    BJU Int; 2008 Nov; 102(9 Pt B):1247-53. PubMed ID: 19035889
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Superficial bladder cancer--treatment approach.
    Abi-Aad A, Biquet P, Penders L.
    Acta Urol Belg; 1996 May; 64(2):19-24. PubMed ID: 8701801
    [No Abstract] [Full Text] [Related]

  • 16. Mitomycin-C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. Finnbladder Research Group.
    Rintala E, Jauhiainen K, Alfthan O.
    Prog Clin Biol Res; 1989 May; 310():271-4. PubMed ID: 2505270
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. BCG-(RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer. EORTC GU Group and the Dutch South-East Collaborative Group.
    Debruyne FM, van der Meijden AP, Franssen MP.
    Prog Clin Biol Res; 1989 May; 303():435-46. PubMed ID: 2506556
    [No Abstract] [Full Text] [Related]

  • 19. Intravesical chemotherapy in the management of superficial bladder tumors.
    Schulman CC.
    Prog Clin Biol Res; 1984 May; 153():275-85. PubMed ID: 6433356
    [No Abstract] [Full Text] [Related]

  • 20. [Superficial bladder cancer: prophylaxis of recurrence and progression].
    Miyanaga N, Akaza H, Koiso K.
    Gan To Kagaku Ryoho; 1991 Nov; 18(14):2369-74. PubMed ID: 1719939
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.